Analysis identifies 50 new genomic regions associated with kidney cancer risk
An international team of researchers has identified 50 new areas across the genome that are associated with the risk of developing kidney cancer. The analysis identified genetic variants associated with the risk of developing papillary renal cell carcinoma and clear cell renal cell carcinoma.
NIH researchers develop AI tool with potential to more precisely match cancer drugs to patients
An artificial intelligence tool called PERCEPTION developed by NCI researchers could one day be used to help doctors more precisely match patients with drugs that will be effective for their cancer.
For childhood cancer survivors, inherited genetic factors influence risk of cancers later in life
Common inherited genetic factors that predict cancer risk in the general population may also predict elevated risk of new cancers among childhood cancer survivors. Findings could potentially inform screening and long-term follow-up of those at greatest risk.
Cancer Grand Challenges selects five new global, interdisciplinary teams to take on four challenges
Interdisciplinary teams will address the following challenges: reducing cancer inequities, understanding the mechanisms of early-onset cancers, developing drugs for solid tumors in children, and broadening our knowledge about how T cells recognize cancer cells.
NIH to address dwindling clinical trial patient enrollment with centralized staffing support
The Virtual Clinical Trials Office aims to tackle the steep decline in participation in NCI- funded cancer clinical trials by providing a centralized team of support staff working remotely to assist with NCI-funded clinical trials activities.
NIH launches research network to evaluate emerging cancer screening technologies
The Cancer Screening Research Network (CSRN) will investigate how to identify cancers earlier, when they may be easier to treat, to ultimately save lives. In late 2024, CSRN plans to launch the Vanguard Study on Multi-Cancer Detection, a pilot study to inform the design of a larger trial of multi-cancer detection tests.
W. Kimryn Rathmell begins work as 17th director of the National Cancer Institute
W. Kimryn Rathmell, M.D., Ph.D., begins her tenure as the 17th director of the National Cancer Institute on December 18, 2023. She comes to NCI from Vanderbilt University Medical Center in Nashville, Tennessee, where she served as the Hugh Jackson Morgan Chair in Medicine, chair of the Department of Medicine, and physician-in-chief.
NCI researchers develop approach that could help supercharge T-cell therapies against solid tumors
New approach may increase the effectiveness of T-cell-based immunotherapy treatments against solid tumors.
NIH immunotherapy pioneer Steven Rosenberg awarded nation’s highest honor for technology and innovation
Steven A. Rosenberg, M.D., Ph.D., has been awarded the National Medal of Technology and Innovation by President Biden. It is the nation’s highest honor for technological achievement.
Annual Report to the Nation Part 2: New cancer diagnoses fell abruptly early in the COVID-19 pandemic
New diagnoses of six major cancer types fell in the early part of the pandemic, according to findings from part 2 of the latest Annual Report to the Nation on the Status of Cancer.